WO2013106944A3 - Méthode de ciblage sélectif de cellules nanoencapsulées dans des organes ou des tissus blancs - Google Patents

Méthode de ciblage sélectif de cellules nanoencapsulées dans des organes ou des tissus blancs Download PDF

Info

Publication number
WO2013106944A3
WO2013106944A3 PCT/CL2013/000003 CL2013000003W WO2013106944A3 WO 2013106944 A3 WO2013106944 A3 WO 2013106944A3 CL 2013000003 W CL2013000003 W CL 2013000003W WO 2013106944 A3 WO2013106944 A3 WO 2013106944A3
Authority
WO
WIPO (PCT)
Prior art keywords
organs
nanoencapsulated
cells
target tissue
selective targeting
Prior art date
Application number
PCT/CL2013/000003
Other languages
English (en)
Spanish (es)
Other versions
WO2013106944A2 (fr
Inventor
Roberto Alejandro EBENSPERGER GONZÁLEZ
Daniel Jordi HACHIM DÍAZ
Original Assignee
Pontificia Universidad Católica De Chile
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pontificia Universidad Católica De Chile filed Critical Pontificia Universidad Católica De Chile
Publication of WO2013106944A2 publication Critical patent/WO2013106944A2/fr
Publication of WO2013106944A3 publication Critical patent/WO2013106944A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6939—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being a polysaccharide, e.g. starch, chitosan, chitin, cellulose or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une méthode et un système de ciblage cellulaire ("cell targeting") destinés à cibler des cellules nanoencapsulées dérivées de tissu humain ou animal dans des tissus ou des organes spécifiques, au moyen d'anticorps conjugués pour une thérapie cellulaire qui a pour but de trouver une solution aux déficiences physiologiques et physiopathologiques par l'administration et/ou l'implantation de cellules vivantes dans des organes ou des tissus blancs de l'organisme humain ou animal.
PCT/CL2013/000003 2012-01-18 2013-01-17 Méthode de ciblage sélectif de cellules nanoencapsulées dans des organes ou des tissus blancs WO2013106944A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CL2012000145A CL2012000145A1 (es) 2012-01-18 2012-01-18 Metodo de direccionamiento celular de celulas a tejidos u organos especificos que comprende las etapas de nanoencapsulacion de celulas con una primera capa que comprende un polication y una capa final que comprende un polianion con grupos carboxilos activados a los cuales se une un anticuerpo especifico contra una celula blanco.
CL145-2012 2012-01-18

Publications (2)

Publication Number Publication Date
WO2013106944A2 WO2013106944A2 (fr) 2013-07-25
WO2013106944A3 true WO2013106944A3 (fr) 2013-09-12

Family

ID=48799764

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CL2013/000003 WO2013106944A2 (fr) 2012-01-18 2013-01-17 Méthode de ciblage sélectif de cellules nanoencapsulées dans des organes ou des tissus blancs

Country Status (2)

Country Link
CL (1) CL2012000145A1 (fr)
WO (1) WO2013106944A2 (fr)

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KROL S.: "Multilayer Nanoencapsulation. New Approach for Immune Protection of Human Pancreatic Islets.", NANO LETTERS, vol. 6, no. 9, 2006, pages 1933 - 1939 *
MESSERSCHMIDT SKE.: "Targeted lipid-coated nanoparticles: Delivery of tumor necrosis factor-functionalized particles to tumor cells.", JOURNAL OF CONTROLLED RELEASE., vol. 137, 2009, pages 69 - 77 *
NAIR HB.: "Delivery of antiinflammatory nutraceuticals by nanoparticles for the prevention and treatment of cancer.", BIOCHEMICAL PHARMACOLOGY, vol. 80, 2010, pages 1833 - 1843 *
VEERABADRAN NG.: "Nanoencapsulation of Stem Cells within Polyelectrolyte Multilayer Shells.", MACROMOLECULAR BIOSCIENCE. 2007., vol. 7, 2007, pages 877 - 882 *

Also Published As

Publication number Publication date
WO2013106944A2 (fr) 2013-07-25
CL2012000145A1 (es) 2014-02-21

Similar Documents

Publication Publication Date Title
WO2012002760A3 (fr) Méthode de diagnostic et de traitement du cancer par des microvésicules cellulaires
MX347893B (es) Conjugados de farmaco y anticuerpo humano contra factor de tejido.
MX2013006591A (es) Formas farmaceuticas orales de liberacion controlada de farmacos escasamente solubles y los usos de estas.
WO2014183066A3 (fr) Modification protéique de cellules vivantes à l'aide de sortase
MX2013005046A (es) Agentes citotoxicos que comprenden nuevos derivados de ansamitocina.
MY191040A (en) Therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2011106788A3 (fr) Peptide car pour le homing, le diagnostic, & la thérapie ciblée pour les troubles pulmonaires et fibrotiques
WO2009100137A3 (fr) Cellules magnétiques utilisées pour localiser une administration et réparer des tissus
BR112018072714A2 (pt) composições de ligação a hcl para e método de tratamento de distúrbios de ácido-base
EP2949344A3 (fr) Utilisation d'enzymes intracellulaires pour libérer des produits bioactifs liés par covalence
WO2016210376A3 (fr) Peptides thérapeutiques et leurs procédés d'utilisation
WO2014006506A3 (fr) Système et méthode de déploiement direct
WO2012048170A3 (fr) Animaux humanisés par ingénierie tissulaire et leurs utilisations
WO2013184922A3 (fr) Procédés d'amélioration du progrès génétique dans une lignée ou race de porcs au moyen de spermatozoïdes sélectionnés en fonction du sexe
SG11201804755VA (en) Method for manufacturing tissue/organ by using blood cells
PH12016501185A1 (en) Compounds to fibrolast growth factor receptor-3 (fgfr3) and therapeutic uses
WO2014028668A3 (fr) Composés thérapeutiques activant les cellules souches
WO2013052158A3 (fr) Nanovecteurs ciblés et leur utilisation pour le traitement de tumeurs cérébrales
EP4321218A3 (fr) Vaccins contre le cancer ciblant des cellules souches cancéreuses
WO2011091154A3 (fr) Utilisation d'érythrocytes humains dans la prévention et le traitement de la dissémination et de la croissance du cancer
WO2011163512A3 (fr) Traitement anticancéreux
MX2015006096A (es) Leucocitos como celulas de administracion para imagen y terapia de enfermedad.
WO2008011473A3 (fr) Compositions et leurs utilisations liées à l'hbxip
WO2013106944A3 (fr) Méthode de ciblage sélectif de cellules nanoencapsulées dans des organes ou des tissus blancs
WO2011133685A3 (fr) Nanoparticule ciblant l'ischémie à des fins d'imagerie et de traitement

Legal Events

Date Code Title Description
122 Ep: pct application non-entry in european phase

Ref document number: 13738040

Country of ref document: EP

Kind code of ref document: A2